Time & Date: 2 September, 15:15 – 16:15 CEST
Chairpersons: L. Arias SPAIN & V. Murro ITALY
Speakers & Presentations:
L. Arias SPAIN
15:15 Welcome
L. Arias SPAIN
15:17 Clinical and genetic landscape of patients with inherited retinal diseases (IRD) in a European reference network member
V. Murro ITALY
15:23 Clinical outcomes of RPE65-related inherited retinal dystrophy patients treated with Voretigene Neparvovec gene therapy: the experience of Careggi Hospital
S.V. Sadda USA
15:29 52 Week Safety and Efficacy of Optogenetic Therapy for Vision Restoration in Retinitis Pigmentosa Patients
K. Lisbjerg DENMARK
15:35 Disease progression of PRPF31-associated retinitis pigmentosa in a Nordic population: A retrospective study with up to 36 years follow-up
M. Großpötzl AUSTRIA
15:41 Progression of Stargardt disease type 4 as measured by spectral-domain optical coherence tomography (SD-OCT) in the ProgStar-4 Study
F. Romano ITALY
15:47 Microperimetry Assessment in Extensive Macular Atrophy with Pseudodrusen-like appearance (EMAP)
L. Colombo ITALY
15:53 Molecular Epidemiology in 591 Italian Probands With Nonsyndromic Retinitis Pigmentosa and Usher Syndrome
E. Panagiotou GREECE
15:59 Studying the genetic basis of inherited retinal diseases (IRDs) in Greece: preliminary results
All Faculty
16:05 Discussion
